Skip to content

Serotonin: all studies

Page 298 of 400: studies 2,971 to 2,980 of 3,999, newest first. Back to the serotonin overview

Research

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin.

Neurotherapeutics 2021 Emmanuelle A. D. Schindler, R Andrew Sewell, Christopher Gottschalk et al. 138 citations

While anecdotal evidence suggests that select 5-hydroxytryptamine 2A (5-HT2A) receptor ligands, including psilocybin, may have long-lasting therapeutic effects after limited dosing in headache disorders, controlled investigations are lacking. In an exploratory double-blind, placebo-controlled, cross-over study, adults with migraine received oral placebo and psilocybin (0.143 mg/kg) in 2 test...

DOI: 10.1007/s13311-020-00962-y (opens in new tab) Full text (opens in new tab) Psilocybin Single dose Migraine headache Lasting therapeutic effects +8

Set and Setting: A Randomized Study of Different Musical Genres in Supporting Psychedelic Therapy

ACS Pharmacology & Translational Science December 29, 2020 Justin C Strickland, Albert Garcia‐romeu, Matthew W. Johnson 89 citations

Mounting evidence supports the serotonin 2A receptor agonist psilocybin as a psychiatric pharmacotherapy. Little research has experimentally examined how session "set and setting" impacts subjective and therapeutic effects. We analyzed the effects of the musical genre played during sessions of a psilocybin study for tobacco smoking cessation. Participants (N = 10) received psilocybin (20-30...

Ketamine reversed short-term memory impairment and depressive-like behavior in animal model of Parkinson's disease.

Brain Research Bulletin December 22, 2020 D. D. Vecchia, L. Kanazawa, E. Wendler et al.

The most common features of Parkinson's disease (PD) are motor impairments, but many patients also present depression and memory impairment. Ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist, has been shown to be effective in patients with treatment-resistant major depression. Thus, the present study evaluated the action of ketamine on memory impairment and depressive-like behavior...

Acute and subacute psychoactive effects of Kambô, the secretion of the Amazonian Giant Maki Frog (Phyllomedusa bicolor): retrospective reports

Scientific Reports December 9, 2020 Timo Torsten Schmidt, Simon Reiche, Caroline L. C. Hage et al. 12 citations

Kambô, the secretion of the Amazonian Giant Leaf Frog (Phyllomedusa bicolor) contains a plethora of bioactive peptides and was originally used by indigenous communities from the Amazon basin as medicine for improving hunting capacities. In the last 20 years, Kambô has spread to Western urban healing circles. To date it is still controversial whether the acute effects of Kambô include...

The entropic tongue: Disorganization of natural language under LSD.

Consciousness and Cognition December 8, 2020 Camila Sanz, Carla Pallavicini, Facundo Carrillo et al. 34 citations

Serotonergic psychedelics have been suggested to mirror certain aspects of psychosis, and, more generally, elicit a state of consciousness underpinned by increased entropy of on-going neural activity. We investigated the hypothesis that language produced under the effects of lysergic acid diethylamide (LSD) should exhibit increased entropy and reduced semantic coherence. Computational analysis...

DOI: 10.1016/j.concog.2020.103070 (opens in new tab) LSD Language Effects Speech disorganization Psychedelic neuroscience

The Ketamine Antidepressant Story: New Insights

Molecules December 7, 2020 Tahani K. Alshammari

Ketamine is a versatile agent primarily utilized as a dissociative anesthetic, which acts by blocking the excitatory receptor N-methyl-d-aspartate receptor (NMDA). It functions to inhibit the current of both Na+ and K+ voltage-gated channels, thus preventing serotonin and dopamine reuptake. Studies have indicated that administering a single subanesthetic dose of ketamine relieves depression...

Toxicology and Analysis of Psychoactive Tryptamines

International Journal of Molecular Sciences December 4, 2020 Sara Malaca, Alfredo Fabrizio Lo Faro, Alice Tamborra et al. 48 citations

Our understanding of tryptamines is poor due to the lack of data globally. Tryptamines currently are not part of typical toxicology testing regimens and their contribution to drug overdoses may be underestimated. Although their prevalence was low, it is increasing. There are few published data on the many new compounds, their mechanisms of action, onset and duration of action, toxicity, signs...

DOI: 10.3390/ijms21239279 (opens in new tab) Tryptamines Pharmacology Toxicology

The Effects of Daytime Psilocybin Administration on Sleep: Implications for Antidepressant Action

Frontiers in Pharmacology December 3, 2020 Daniela Dudysová, Karolína Janků, Michal Šmotek et al. 37 citations

Serotonergic agonist psilocybin is a psychedelic with antidepressant potential. Sleep may interact with psilocybin’s antidepressant properties like other antidepressant drugs via induction of neuroplasticity. The main aim of the study was to evaluate the effect of psilocybin on sleep architecture on the night after psilocybin administration. Regarding the potential antidepressant properties, we...

DOI: 10.3389/fphar.2020.602590 (opens in new tab) Psilocybin Antidepressant Slow-wave sleep Sleep spindle +4

The psychoactive aminoalkylbenzofuran derivatives, 5-APB and 6-APB, mimic the effects of 3,4-methylenedioxyamphetamine (MDA) on monoamine transmission in male rats.

Psychopharmacology December 2020 Simon D. Brandt, Hailey M Walters, John S. Partilla et al.

The nonmedical use of new psychoactive substances (NPS) is a worldwide public health concern. The so-called "benzofury" compounds, 5-(2-aminopropyl)benzofuran (5-APB) and 6-(2-aminopropyl)benzofuran (6-APB), are NPS with stimulant-like properties in human users. These substances are known to interact with monoamine transporters and 5-HT receptors in transfected cells, but less is known about...

DOI: 10.1007/s00213-020-05648-z (opens in new tab) Full text (opens in new tab) Benzofury Designer drugs Locomotor activity MDMA, Mda +4

Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review

Molecular Biology Reports December 1, 2020 Alec J. DiVito, Robert F. Leger

Classical psychedelics are a group of drugs characterized by their activation of the serotonin-2A (5-hydroxytryptamine-2A; 5-HT2A) receptor and the unique hallucinogenic and mystical-type experiences that result. After a substantial period of restrictions limiting investigations into the therapeutic potential of psychedelics, a relatively recent recommencement of interest has sparked the...

DOI: 10.1007/s11033-020-06009-x (opens in new tab) Full text (opens in new tab) Addiction Smoking cessation Psychedelics Serotonergic hallucinogen